SRPT
Undervalued by 712% based on the discounted cash flow analysis.
Market cap | $1.97 Billion |
---|---|
Enterprise Value | $3.20 Billion |
Dividend Yield | $0 (0%) |
Earnings per Share | $2.34 |
Beta | 0.6 |
Outstanding Shares | 97,362,000 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -7.87 |
---|---|
PEG | 0.59 |
Price to Sales | 0.86 |
Price to Book Ratio | 1.72 |
Enterprise Value to Revenue | 1.43 |
Enterprise Value to EBIT | -16.35 |
Enterprise Value to Net Income | -13 |
Total Debt to Enterprise | 0.46 |
Debt to Equity | 1.29 |
No data
No data
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the...